People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immune Design Corp. | — | Biotechnology | Series C | $144.6M | $2.0B | 2010 |
| Aerovance Inc | — | Biotechnology | Series B | $22.5M | $19.8M | 2009 |
| Lead Therapeutics, Inc. | — | Biotechnology | Seed | $3.0M | $133.2M | 2009 |
Alain Schreiber at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alain Schreiber on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Richard Klausner | 1 | 7 |
| Brian Atwood | 1 | 6 |
| Mark Perry | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Douglas E. Williams | 1 | 4 |
| Arthur Pappas | 1 | 3 |
| Nick Galakatos | 1 | 3 |
| James Paul Rickey | 1 | 3 |
| Leonard Post | 1 | 3 |
| Steven Reed | 1 | 2 |
| ANTHONY RIMAC | 1 | 2 |
| David Baltimore | 1 | 2 |
| Peter V. Svennilson | 1 | 2 |
| Shuang Qiao | 1 | 2 |
| Nicholas G. Galakatos | 1 | 2 |
| Sammy Farah | 1 | 2 |
| Stephen R. Brady | 1 | 2 |
| Edward Penhoet | 1 | 2 |
| Bruce Carter | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.